UroGen Pharma Reports Final Data From Key Trials Evaluating UGN-102 And Jelmyto

(RTTNews) - UroGen Pharma Ltd. (URGN) reported final data from two key trials with investigational agent UGN-102 (mitomycin) for intravesical solution in adult patients with low-grade intermediate risk non-muscle invasive bladder cancer and Jelmyto (mitomycin) for pyelocalyceal solution in adult patients with low-grade upper tract urothelial cancer.

The company said the final OPTIMA II trial results showed that 65% of patients receiving UGN-102 achieved a complete response three months after the start of therapy.

The results of the phase 3 OLYMPUS trial of Jelmyto, the non-surgical kidney-sparing treatment approved by the FDA for adults with LG-UTUC, showed clinically meaningful response in adults with low-grade upper tract urothelial cancer.